Animal Parasiticide Market Size, Share, and Growth Forecast, 2025 - 2032

The global animal parasiticide market size is likely to be valued at US$13.4 Bn in 2025 and is estimated to reach US$20.7 Bn in 2032, growing at a CAGR of 6.4% during the forecast period 2025-2032.

Key Industry Highlights:

• Government Initiative: The Cross-Government Pharmaceuticals in the Environment (PiE) Group announced new plans to address the presence of chemicals from flea and tick treatments in rivers and streams across the U.K. It focuses on two chemicals, namely, fipronil and imidacloprid, which are commonly used in topical parasite treatments for pets.
• Leading Animal Type: Production animals hold nearly 59.4% share in 2025, owing to rising demand for meat, dairy, and poultry products.
• Dominant Product Type: Ectoparasiticides, approximately 49.1% of the animal parasiticide market share in 2025, as external parasites cause immediate health issues, making spot-ons, collars, and injectables the preferred options for visible protection.
• Leading Region: North America, with about 35.3% share in 2025, due to novel veterinary infrastructure and ongoing regulatory approvals for new products, including long-acting injectables.
• Fastest-growing Region: Europe, backed by rising awareness of animal welfare and adoption of combination treatments.

The animal parasiticide market growth is driven by rising pet ownership, increasing livestock production, and surging awareness of parasite-related diseases. Key companies are following novel strategies such as the development of long-acting injectables, combination oral and spot-on treatments, and integrated herd-level solutions to improve product efficacy and convenience. 

Livestock Productivity Losses Accelerate Demand Worldwide

The rise in animal parasitic infections is propelling demand for parasiticides as increased infestation rates threaten both animal health and productivity. In companion animals, high flea, tick, and worm infections are leading to more cases of dermatitis, anemia, and zoonotic disease transmission. This is making pet owners more vigilant about preventive care. In production animals, parasitic infections tend to reduce growth, milk yield, and meat quality, directly affecting farmers’ revenues.

Recent outbreaks of liver flukes in sheep in Europe and gastrointestinal worms in dairy cattle in India have highlighted the economic impact of uncontrolled parasites. This has accelerated the use of both endoparasiticides and ectoparasiticides in herds and flocks. These are often used in combination or integrated management programs to maintain productivity and prevent disease spread. The rise of parasitic infections is also fueling development in treatment formats. Long-acting injectables, combination spot-on treatments, and medicated feeds are gaining traction as they reduce labor and ensure consistent coverage.

Environmental Risks Limit the Use of Spot-on Treatments and Medicated Collars

Environmental concerns are increasingly shaping the adoption of veterinary parasiticides. Spot-on treatments and medicated collars, while convenient for pet owners, can wash off during bathing or rain and enter wastewater systems. Studies in Europe and North America have shown that residues of active ingredients such as fipronil and imidacloprid can accumulate in rivers, negatively affecting aquatic invertebrates such as crustaceans and insects. It has prompted regulators and environmental agencies to issue guidelines limiting use near water bodies, which tends to reduce pet owners’ willingness to apply these products freely.

The environmental risk is relevant in urban and suburban areas with high densities of pets and nearby waterways. For example, certain local authorities in Germany and France have launched awareness campaigns about the ecological impact of topical parasiticides. These are encouraging pet owners to consider alternatives or to avoid over-application. It has created a hesitation in adoption, mainly among environmentally conscious consumers who might prefer oral or long-acting injectables that minimize runoff.

Multi-Parasite Products Simplify Treatment and Increase Compliance

The development of single products that control multiple types of parasites is creating new opportunities by simplifying treatment regimens for both pet owners and farmers. Products that combine ectoparasiticides and endoparasiticides in one formulation reduce the requirement for multiple applications, which increases compliance and improves parasite control. For veterinarians, combination products create opportunities to increase treatment efficiency and client trust.

When a single product can address multiple parasites, vets can provide comprehensive solutions during a single visit, which strengthens customer loyalty. In livestock, multi-parasite products reduce labor and improve herd-level control. Medicated feeds or injectables that target both internal and external parasites allow farmers to treat entire herds simultaneously. These help in ensuring more consistent protection and reducing losses from parasite-related health issues.

Animal Type Insights

Based on animal type, the market is bifurcated into production and companion animals. Among these, production animals are predicted to account for nearly 59.4% of the market share in 2025, as parasites directly impact both animal health and farm economics. Infestations in cattle, poultry, and swine can reduce growth rates, egg production, milk yield, and meat quality. For example, in dairy farms across India and China, gastrointestinal worms and ticks are a leading cause of decreased milk output, prompting the widespread use of dewormers and acaricides to maintain productivity.

Companion animals are seeing steady growth as pet ownership is rising considerably, especially in urban areas across North America, Europe, and Asia Pacific. More households are treating pets as family members, spurring demand for products that protect against fleas, ticks, and intestinal worms. Another factor is the growing preference for combination and long-acting products. Owners prefer solutions that target multiple parasites with fewer doses, reducing the hassle of monthly treatments. There is also an increasing focus on veterinary guidance, health monitoring, and preventive care, with products now integrated into subscription services and tele-vet platforms.

Product Type Insights

By product type, the market is trifurcated into ectoparasiticides, endoparasiticides, and endectocides. Out of these, ectoparasiticides are anticipated to hold around 49.1% share in 2025, as external parasites such as fleas, ticks, and mites have immediate and visible effects on animal health and welfare. Infestations can cause severe irritation, anemia, dermatitis, and even transmit serious diseases such as Lyme disease in dogs or tick-borne fever in cattle. This immediacy makes farmers and pet owners more likely to prioritize prevention and treatment with ectoparasiticides over internal parasite control.

Endoparasiticides are seeing steady growth as internal parasites such as roundworms, hookworms, and tapeworms can silently affect animal health, often without obvious symptoms. In production animals, these parasites reduce weight gain, milk production, and productivity. In pets, they tend to cause gastrointestinal distress and transmit zoonotic diseases. The hidden nature of these infections has increased the demand for routine preventive treatments, rather than waiting for visible signs of illness.

North America Animal Parasiticide Market Trends - Fast Regulatory Action Strengthens U.S. Response to Parasite Outbreaks

North America will likely account for approximately 35.3% of the market share in 2025, due to fast regulatory action and constant development. In the U.S. animal parasiticide market, the Food and Drug Administration (FDA) was given the power to issue emergency approvals for animal drugs to fight the New World Screwworm, a dangerous parasite threatening livestock near the Mexican border. This shows how quickly the country is prepared to act against parasite outbreaks to protect both animals and the food supply.

For companion animals, companies are focusing on long-lasting and convenient products. Zoetis, for example, broadened the use of Simparica Trio, making it the only product in the U.S. approved to prevent flea-tapeworm infections. Livestock is further seeing new solutions. In 2025, Merck received FDA approval for Exzolt, an oral treatment for mite infestations in chickens. This is important for poultry producers, as mites can reduce egg production and harm flock health.

Europe Animal Parasiticide Market Trends - Strict EMA Norms Propel Careful Monitoring of Antiparasitic Drug Resistance

In Europe, the market is being spurred by strict regulations and a rising focus on safety. The European Medicines Agency (EMA) has recently increased its monitoring of parasite drug use. It includes close checks on resistance in drugs such as albendazole used for sheep. This shows that regulators are not only approving new medicines but also keeping a close eye on how existing ones are used to prevent overuse and resistance.

New products are coming into the regional market that focus on long-term protection and combination treatments. For instance, Vetoquinol launched Felpreva, a spot-on for cats that lasts three months and covers multiple parasites such as worms and fleas. Another important trend in Europe is the ongoing push for sustainability and reduced use of antibiotics. Industry groups have pledged to invest in vaccines and better veterinary education to prevent disease before it requires intensive drug treatment.

Asia Pacific Animal Parasiticide Market Trends- Rising Pet Ownership and Livestock Expansion Fuel Parasiticide Demand

The market is rising steadily in Asia Pacific due to increasing pet ownership in cities and the expansion of livestock industries. China and India are seeing high demand as pet care becomes a priority for urban families. Dairy and poultry farms are investing heavily in parasite control to improve productivity and meet export standards. A key step was the launch of the Asia Pacific Association of Veterinary Parasitology in 2024, supported by Boehringer Ingelheim.

The group aims to bring together veterinarians, researchers, and companies across the region to share knowledge and improve parasite control programs. It exhibits how collaboration is becoming important in tackling regional challenges such as resistance and lack of awareness. For livestock, companies are focusing on practical solutions such as parasiticide-mixed feeds and digital tools that track dosage and timing. These are being adopted in commercial swine and poultry farms across China and Southeast Asia to improve efficiency.

The global animal parasiticide market is highly consolidated, with a few big players such as Zoetis, Merck, Elanco, and Boehringer competing closely. These companies are focusing less on just new active ingredients and more on making treatments more convenient and long-lasting. Much of the competition now centers around combination products that treat both internal and external parasites in one dose. Marketing strategies are also becoming more evidence-backed. Companies are running head-to-head studies to show their drugs work faster or last longer than rivals. They are leveraging this data to win over veterinarians.

Key Industry Developments

• In July 2025, MSD Animal Health bagged the U.S. FDA approval for BRAVECTO QUANTUM. It is a new, once-yearly injectable product to treat and protect dogs against fleas and ticks. The product is anticipated to be made available at veterinary clinics and hospitals in the U.S. by August 2025.
• In January 2025, Lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets were officially launched by Elanco Animal Health. The product provides canine protection against six parasites and made its debut at the 2025 Veterinary Meeting & Expo (VMX) in Orlando.